# Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

> **NCT01241682** · PHASE1 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Malignant (Pleural) Mesothelioma

## Interventions

- **BIOLOGICAL:** DC + CTX

## Key facts

- **NCT ID:** NCT01241682
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-10
- **Final completion:** 2012-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241682, "Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01241682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*